Jazz Pharmaceuticals (JAZZ) Income from Non-Controlling Interests (2014 - 2025)
Jazz Pharmaceuticals (JAZZ) posted quarterly Income from Non-Controlling Interests of -$147000.0 for Q1 2025, down 108.55% year-over-year from $1.7 million in Q1 2024, and down 108.55% quarter-over-quarter from $1.7 million in Q1 2024.
Powered by 
Analysis
Jazz Pharmaceuticals (JAZZ) Income from Non-Controlling Interests (2014 - 2025) Analysis & Trends
Jazz Pharmaceuticals' Income from Non-Controlling Interests history runs 4 years deep, the most recent figure standing at -$147000.0 for Q1 2025.
- In Q1 2025, Income from Non-Controlling Interests fell 108.55% year-over-year to -$147000.0; the TTM figure through Mar 2025 stood at $1.6 million (down 8.55% YoY), while the FY2015 annual figure was -$1000.0, up 99.91% from the prior year.
- Income from Non-Controlling Interests for Q1 2025 stood at -$147000.0, down from $1.7 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $1.7 million in Q1 2024, with the low at -$147000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Jazz Pharmaceuticals | 15.60 Bn | 13.98 Bn | 1.09 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | -147,000.00 |
| Mar 31, 2024 | 1.72 Mn |
| Jun 30, 2015 | -1,000.00 |
| Dec 31, 2014 | -1,000.00 |
| Sep 30, 2014 | 2,000.00 |
| Jun 30, 2014 | -73,000.00 |
| Mar 31, 2014 | -989,000.00 |